MALAT1 and metabolic dysfunction-associated steatotic liver disease: Another study reported that blood levels of lncRNA MALAT1 and HULC rise with advanced fibrosis, suggesting they might complement FIB-4 in identifying high-risk MASLD patients [39,122,123].